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Summary  
Fatigue is a frequent and distressing symptom in patients with multiple sclerosis (MS). In 
contrast, sleepiness, characterized by difficulties to stay awake and alert during the day, seems 
to be less prevalent in MS; however exact studies are lacking. In addition, there is a semantic 
confusion of the concepts of “fatigue” and “sleepiness”, which are often used 
interchangeably. We conducted a systematic review of studies using the Epworth sleepiness 
scale (ESS) for the assessment of daytime sleepiness in patients with MS. The summarized 
results of 48 studies demonstrate that sleepiness, as indicated by elevated ESS scores, is less 
prevalent and less severe than fatigue but is present in a significant proportion of patients with 
MS. In most cross-sectional and longitudinal studies, there was a moderate association 
between ESS scores and various fatigue rating scales. Longitudinal studies on the effect of 
wakefulness-promoting agents failed to show a consistent improvement of sleepiness or 
fatigue as compared to placebo. It has also been shown that daytime sleepiness is frequently 
associated with comorbid sleep disorders that are often underrecognized and undertreated in 
MS. Sleepiness and potential sleep disorders may also precipitate and perpetuate fatigue in 
patients with MS and should be part of the differential diagnostic assessment. To support an 
appropriate decision-making process, we propose an algorithm for the evaluation of 
sleepiness as compared to fatigue in patients with MS. 
Keywords: Multiple sclerosis; fatigue; daytime sleepiness; Epworth sleepiness scale; 
systematic review 
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List of abbreviations 
 
 
 
  
  
CPAP  continuous positive airway pressure 
ESS  Epworth sleepiness scale 
FIS  fatigue impact scale 
FSS  fatigue severity scale 
ICSD-3 International classification of sleep disorders (third edition) 
MFIS  modified fatigue impact scale 
MS  multiple sclerosis 
NFI-MS neurological fatigue index 
PLMD  periodic limb movement disorder 
PSG  polysomnography 
PSQI  Pittsburgh sleep quality index 
RLS  restless legs syndrome 
SRBD  sleep-related breathing disorder 
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Introduction 
Multiple sclerosis (MS) is an inflammatory, demyelinating and neurodegenerative 
autoimmune disease of the central nervous system (CNS) [1]. It is the leading cause of non-
traumatic neurologic disability in young adults [2]. MS is a chronic disease, whose clinical 
course can be defined as relapsing-remitting (RRMS), primary-progressive (PPMS) and 
secondary-progressive (SPMS), and progressive-relapsing (PRMS) 
(http://www.nationalmssociety.org) active or inactive and progressive or non-progressive [3]. 
It involves a spectrum of neurologic symptoms, such as sensory disturbances, impaired 
vision, paresis, gait difficulties and bladder dysfunction. In addition, fatigue, as well as 
cognitive decline, reflects the presence and distribution of damage in the CNS and may vary 
considerably among individuals. MS-related fatigue is ascribed to multifactorial etiologies 
including inflammatory cytokines, nocturia, pain, infection, anxiety and depression [4]. In 
addition, poor sleep and sleep disorders, such as restless legs syndrome (RLS), have been 
identified as contributing factors for MS-related fatigue and are more common in MS patients 
compared to healthy controls [5,6].  
It is reported that 53-92% of patients with MS are affected by fatigue and as many as 46-66% 
suffer on a daily basis [7–12]. Fatigue is a disabling symptom that can be described as a 
feeling of tiredness, exhaustion, weariness or lassitude. It is commonly measured by self-
rating scales such as the fatigue severity scale (FSS) [13]. In about one third of the patients, 
fatigue may present as the initial symptom of MS [14]. Overall, 28-60% of patients report that 
fatigue is their most distressing symptom [12, 14, 15], being a major cause of unemployment 
and early retirement in MS [16, 17]. Severe fatigue is also related to increased instances of 
physical disability, neurological impairment and mobility impairment (e.g., bedridden patients 
reported the most severe fatigue) [16].  
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Fatigue is distinct from sleepiness, which is defined by the International Classification of 
Sleep Disorders (ICSD-3) as the inability to stay awake and alert during the day, leading to 
episodes of an irrepressible need for sleep or unintended lapses into drowsiness or sleep [18] 
(Table 1). Sleepiness predisposes people to develop serious performance impairments in daily 
functioning and is a risk factor for potentially life-threatening domestic, occupational, and 
vehicular accidents [18]. The complaint of excessive sleepiness during the normal wake 
period is also a pivotal symptom for sleep disorders of hypersomnolence, as classified by the 
ICSD-3. 
--- Insert Table 1 about here --- 
Recently, sleep disorders in MS, as well as the causes and consequences of daytime sleepiness 
in patients with MS, have gained more attention in research, suggesting that sleepiness is an 
underrecognized and overlooked symptom in MS. In contrast to the huge body of literature on 
the presence of fatigue in MS, to our knowledge, there is no systematic epidemiological study 
on the frequency of sleepiness in MS.  
The wide spectrum of fatigue prevalence rates in MS patients may be due to the use of 
different assessment methods based on various definitions and interpretations of the term 
“fatigue”. In clinical practice as well as in the scientific literature, “fatigue” and “sleepiness” 
are frequently used interchangeably [19]. Individuals may even subsume both terms under the 
complaint of “being tired”. Nevertheless, “fatigue”, “sleepiness” or “tiredness” refer to 
distinct concepts and provide different semantic connotations [20]. The need to distinguish 
between fatigue and sleepiness is supported by other studies showing that both conditions 
substantially differ in implications for diagnosis and treatment, subjective experience, and 
their underlying neurobiological mechanisms [19, 21, 22]. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 Sleepiness in multiple sclerosis   6 
__________________________________________________________________________________ 
 
 
 
A widely used approach to evaluate daytime sleepiness on a subjective level, is the 
employment of the Epworth sleepiness scale (ESS), a self-administered 8-item questionnaire 
assessing sleep propensity [23]. A total ESS score greater than 10 (range 0 to 24) is indicative 
for increased sleepiness. In the instructions, the ESS asks for the likelihood of dozing off or 
falling asleep in different everyday situations, “in contrast to feeling just tired“[23]. Thus, the 
ESS quantifies daytime sleepiness using behavioral correlates and circumvents subjective 
evaluations of states of tiredness, sleepiness or fatigue. Assessing sleepiness by this approach 
avoids semantic confusion, which is a problem when using fatigue questionnaires that are 
based on self-reports. 
The aim of this systematic review is to summarize the results of published studies using the 
ESS for the assessment of daytime sleepiness in patients with MS. We focused on the 
frequency and extent of daytime sleepiness compared to fatigue as assessed by self-
administered rating scales such as the FSS or other related scales (e.g. neurological fatigue 
index, NFI-MS, modified fatigue impact scale, MFIS).   
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Methods 
Literature search and identification of studies  
Studies were identified by searching electronic databases and scanning reference lists of 
articles. The present review only includes studies that used the ESS, which was published in 
1991, as an assessment-tool. Therefore, articles that were published before 1991 were not 
considered. No other limits (e.g. language restrictions) were applied. The search strategy was 
developed by a subject specialist (RP) in collaboration with an information specialist and 
librarian who is trained and experienced in conducting comprehensive literature searches 
(HK). Database searches were conducted by HK on May 14, 2014, with an update on April 
22, 2015. In addition, registers for clinical trials were searched on August 04, 2015. While our 
search strategy was not peer-reviewed, we strived to design, carry out and report the literature 
search according to current checklists and recommendations [24, 25]. 
The research question was translated into two search concepts, “multiple sclerosis” and 
“Epworth sleepiness scale” that were combined using the Boolean operator AND. The search 
strategy was adapted to the various databases and search interfaces. This included selecting 
feasible search terms, syntax, and relevant subject headings. The searches were designed to be 
sensitive and potentially over-inclusive to avoid missing any relevant articles. We searched 28 
medical and psychological reference databases hosted by DIMDI, including MEDLINE, 
Embase, Cochrane Database of Systematic Reviews, and Cochrane Central Register of 
Controlled Trials. In addition, a full text search was conducted in PubMed Central. In Web of 
Science Core Collection, we searched for studies on MS that cite the original article about the 
“Epworth sleepiness scale” by Johns, [23]. Several dissertation databases and four registers 
for clinical trials were also consulted.  
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A detailed documentation of the searches allowing for replication, can be seen in Appendix 1, 
which is available as an electronic supplement. The reference lists of articles that were 
regarded eligible were scanned by AF, NK, and RP. 
Eligibility assessment 
Eligibility assessment was performed independently in a standardized manner by three 
reviewers (RP, AF, and NK). Disagreements were solved by consensus. If no agreement could 
be reached, another author (TCW) was designated to make the final decision. Studies were 
included only if the contained the following: (a) original investigations - articles in which no 
original data was published were excluded (e.g. mostly reviews, letters to the editor etc.). (b) 
published ESS data - the article had to provide statistical data of the ESS score (e.g. mean, 
median). (c) adult (≥ 18 years) patients with MS. (d) sufficient sample sizes, (n ≥ 10) that 
allowed for inferential statistics, i.e. no case reports or studies providing only descriptive data. 
Finally, no restrictions concerning duration of illness, subtype of MS or other specifications 
were applied. We also did not limit this review to studies with special interventions.  
Data extraction  
A data-extraction sheet was developed and pilot-tested on 10 pseudo-randomly selected 
articles. After applying some adaptive changes, it was used for extracting information from all 
included studies (see Table S1 - Appendix 3). The data extraction was performed by one of 
the authors (AF) and examined by another (NK). If there were any ambiguities concerning the 
data it was discussed by a committee of three additional authors (RP, RW, and TCW). From 
each study we extracted the information presented in Tables 2 and 3. 
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Results 
Study selection  
Disagreements regarding eligibility assessment between the reviewers (AF, RP, and NK) were 
minor and could be resolved by consensus. Our cross-database search yielded 607 records. 
After removing duplicates, 521 records remained and were screened for relevance. 440 
records were excluded because no original data was published, disorders other than MS were 
investigated (e.g. sleep disorders, Parkinson`s disease), or there was no ESS data specified in 
the abstract and no full text articles were available. If the record was categorized as 
potentially relevant, the full text article was assessed for eligibility. 21 studies were not 
included because the ESS was not used as an assessment tool. In three studies, the number of 
participants was too small (< 10) to be included. One of the full text articles was excluded 
because the patients were younger than 18 years of age. Ten of the full text articles were 
excluded because no sufficient statistical ESS data was published. However, if the 
corresponding author of these studies could provide ESS data on request, the articles were 
included in the study selection (n = 5; see supplementary material - Appendix 2). Finally, our 
systematic review comprised 48 studies (Table 2) [26-73]. 
--- Insert Table 2 about here --- 
The flow diagram of the selection process is presented in Figure 1. Detailed information of 
articles excluded by full-text review is given in Appendix 4 of the supplementary material. 
--- Insert Figure 1 about here --- 
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Review findings 
No systematic epidemiological studies on the prevalence of daytime sleepiness in MS patients 
using the ESS as a main outcome parameter have been published so far. Out of 48 original 
articles, about one-third (30%) of the studies comprised a larger MS sample size, i.e. at least 
100 patients were included. The majority of articles (67%) had a cross-sectional study design, 
while the others, in most cases, used a long-term longitudinal study design to assess different 
treatment effects of medication and other interventions such as treatment of sleep disorders 
[58–72]. In particular, two studies investigated the effect of continuous positive airway 
pressure (CPAP) treatment on respiratory disturbances occurring during sleep, which are 
defined as sleep-related breathing disorder (SRBD) [61, 64]. As the ESS and FSS are trait-
specific questionnaires, potential improvements of both scores depend on lasting interventions 
(i.e., from one week to several months). Thus, we did not consider temporary 
pharmacological effects lasting only a few hours as longitudinal data [51]. We also used 
baseline results of longitudinal studies to gain cross-sectional data on ESS- and fatigue scores. 
Out of all investigations, 19 studies provided data on the correlation between the ESS and the 
FSS (89%) or other fatigue scales (e.g. NFI-MS, MFIS). Finally, for objective measures of 
sleep disorders in MS patients, nine studies using polysomnography (PSG) [27, 30, 33, 36, 40, 
41, 49, 56, 61] and two study applying actigraphy [26, 65] were used.  
Cross-sectional data 
Among the studies reporting on fatigue levels (n = 40), increased fatigue scores (e.g. FSS > 4 
or MFIS > 34) were found in the vast majority (78%) and were mostly well above their 
critical cut-offs. Increased daytime sleepiness, as defined by a mean ESS score above 10, was 
detected in 11 studies (23%) reporting ESS values in either total samples or subgroups of 
patients. The largest non-systematic survey of sleep disorders in the MS population to date, 
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comprising 2,375 patients, suggests increased daytime sleepiness in 30% of the respondents 
based on an ESS score above 10 [31] (see Table 2). Within the patient groups, elevated mean 
ESS scores mostly ranged from 10.5 to 12.5 and were close to their critical cut-off value. 
Only a single study, with 21 fatigued MS patients, showed a higher mean ESS score for the 
whole group (15.7) [33]. On an individual level, the proportion of MS patients with elevated 
ESS scores was up to 61% in those studies that provided frequency data (23 studies in total). 
Six studies with population sizes of at least 100 MS-patients reported frequencies of increased 
ESS scores between 19% and 53%. 
Among the 19 studies that investigated the correlation between ESS and fatigue scores, six 
found no significant correlation between the two [28, 41, 47, 48, 53, 54]. The other studies 
reported low [45] to high correlations [33] (from r = 0.18 to 0.74) with most correlations 
being in the moderate range (r = 0.30 to 0.47) [30, 34, 35, 38, 40, 44, 46, 51, 55]. Several 
studies using PSG or actigraphy found an association between an increased level of sleepiness 
or fatigue and objectively measured sleep disorders such as disrupted sleep/abnormal sleep 
cycles [26], impaired sleep quality [33, 41, 49, 56], periodic limb movement disorder (PLMD) 
[27] or SRBD [40, 61]. Only one polysomnographic study did not find a difference in the 
sleep parameters between the fatigued versus non-fatigued MS-patients [36]. 
Longitudinal data 
Our search yielded 16 studies reporting ESS data at baseline and at follow-up (see Table 3). 
Six studies specifically evaluated the efficacy of wakefulness-promoting agents (e.g. 
modafinil or armodafinil) on fatigue or sleepiness. In two placebo-controlled studies, 
modafinil [66] or armodafinil [60] did not significantly improve fatigue or sleepiness at all. 
Among two further studies using placebo, one demonstrated a substantial placebo effect on 
fatigue with no additional benefit from modafinil [68], whereas the other study only reported 
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significant improvements in fatigue compared to the placebo run-in phase [67]. Two non-
placebo-controlled studies with modafinil showed significant improvement on either both 
fatigue and sleepiness [72] or fatigue alone [59]. The impact of other medications focusing on 
various clinical effects (e.g. on sleep quality or as disease-modifying immunotherapies) was 
assessed by five other studies. In two placebo-controlled studies, the hypnotic agent 
eszopiclone had no significant effect on ESS or FSS [58], while the nightly sublingual 
administration of the antispasmodic drug tizanidine significantly reduced next-day spasticity 
and was associated with a reduction of the ESS-score. This effect was unexpected, since day-
dose tizanidine typically increases daytime hypersomnolence reduced sleepiness [70]. In three 
observational studies involving immune modulatory drugs, natalizumab improved both 
sleepiness and fatigue [69], whereas interferon-beta, which may provoke sleep disturbances, 
did not change [65] or even negatively affected both conditions in the long term [63]. The 
injection of interferon-beta impaired sleep efficiency during the following night and led to 
short-term effects of sleepiness and fatigue during the next day [65]. 
Three of the 16 longitudinal studies investigated the effects of sleep disorder treatment. One 
study showed a significant improvement of both fatigue and sleepiness, particularly for the 
treatment of SRBD [61]. Two other studies found that either CPAP-therapy [64] or treatment 
of different sleep disorders (e.g. RLS, PLMD, insomnia, SRBD) [73] were associated with a 
significant but moderate decrease of FSS scores, whereas ESS scores did not change. 
Participants of a cognitive behavioral therapy group improved significantly more over time (6 
month follow-up) than participants of relaxation training, in terms of fatigue as assessed by 
the FSS. Such an improvement was not found for the ESS [71]. In a single study, an energy 
conservation program to manage fatigue was tested [62]. Significant improvement of 
cognitive scores on the fatigue impact scale (FIS) could be observed, but no significant 
changes in all other outcome variables, including FSS and ESS, were found.  
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--- Insert Table 3 about here---- 
 
Discussion 
In our comprehensive literature search we strived to find all available evidence on the use of 
the ESS as an assessment tool in adult patients with MS. Finally, we identified 48 studies that 
fulfilled our inclusion criteria.  
The majority of studies showed clinically significant fatigue in MS, whereas sleepiness was 
reported to be less frequent and less severe. Nevertheless, a substantial number of fatigued 
patients showed increased ESS scores as well. Some studies investigating the association 
between sleepiness and fatigue revealed weak to moderate correlations between both 
conditions, mainly depending on the presence of comorbid sleep disorders. In general, sleep 
disorders such as SRBD [61, 74] or PLMD [27] and impaired sleep quality are often 
associated with fatigue or sleepiness [33, 56]. Importantly, the small number of available 
placebo-controlled, interventional studies showed that wakefulness-promoting agents, such as 
modafinil or armodafinil, were not consistently effective to reduce either sleepiness or fatigue 
in the long-term [60, 66, 68]. These findings are in line with a 2015 Cochrane database review 
reporting weak and inconclusive evidence for the efficacy of stimulants, such as modafinil, 
pemoline or amantadine, as pharmacological treatments for fatigue in MS [75]. 
The extent of sleepiness and fatigue in MS  
In almost all (85%) selected studies using the ESS as an assessment tool, fatigue scores 
(typically measured with the FSS) were also presented. Increased fatigue in patients with MS, 
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as indicated by elevated fatigue rating scores, was present in the majority (78%) of the 
reviewed studies that provided fatigue data. This finding is in accordance with previous 
epidemiological studies that showed high prevalence of fatigue in patients with MS [7–10]. 
In contrast, increased daytime sleepiness (mean ESS score > 10) was observed less frequently 
(26% of the studies), comprising a limited number of patients with MS (see Table 2). Two 
studies reporting mean ESS scores of 15.0 and 15.7 referred to two subgroups that were a 
priori defined as sleepy or fatigued comprising only 6 (total n = 12) or 11 (total n = 21) MS 
patients, respectively. [27, 33]. Of note, the study by Beran and colleagues [27] used the ESS 
as a specific selection criterion (ESS score ≥ 9) for patients with and without daytime 
sleepiness. In few other studies indicating pathological sleepiness on a group level, patients 
were selected regarding fatigue (fatigue descriptive scale ≥ 5) in combination with complaints 
of sleep disturbances [58]. This was particularly the case for interventional studies 
investigating the efficacy of wake-promoting substances [66, 68]. In some other studies 
showing increased ESS scores in patient subgroups, the patients had specifically been selected 
for increased fatigue levels [26, 33, 39, 56].  
In all studies with more than 150 MS patients, the mean ESS score did not indicate increased 
sleepiness. In the two largest samples of MS patients by Mills and Young [47] (n = 559 with 
valid ESS data) and Brass and colleagues [31] (n = 2,375), the average ESS scores were 7.9 
(mean) and 8 (median), respectively - well below the critical cut-off score. Despite the low 
mean ESS scores of the study sample published by Brass and colleagues [31], 30% of the 
patients scored above 10, indicating increased sleepiness. In general, daytime sleepiness does 
not seem to be a prominent and frequent symptom in MS patients on a group level, but may 
be present in a substantial number of patients (ranging up to 61%) on an individual level 
(Table 2).  
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The association of sleepiness and fatigue  
The majority of studies typically showed increased fatigue scores without overlapping 
sleepiness. Only one single study, comprising no more than 14 MS patients found increased 
ESS scores without corresponding elevated fatigue levels [60]. Our results indicate that 
fatigue without sleepiness is frequent, while sleepiness without fatigue is rare. Thus, if 
pathological fatigue is present, ESS scores can be either high or low. These findings are in 
accordance with a pilot study by Merkelbach and Schulz [22], indicating that sleepiness may 
vary to a noticeable extent independently from fatigue. The authors also suggest sleep 
disorders as a critical intervening factor that amplifies sleepiness in a subgroup of fatigued 
MS patients [46]. By extending their preliminary results in a larger study, the authors 
demonstrated in a single-item analysis of the ESS that only a subset of ESS items referring to 
self-paced activation for functioning was closely associated with fatigue as assessed by the 
FSS [46].  
Few studies specifically distinguished between the concepts of sleepiness versus fatigue on a 
semantic level [27, 46], while 19 studies investigated the relationship between both clinical 
conditions in more detail. These studies, which explored the relationship between the ESS as 
a main outcome parameter and fatigue scales found mainly moderate correlations between 
both conditions.  
Semantic confusion of concepts  
Sleepiness and fatigue are two interrelated but distinct phenomena [19], that can be easily 
confused [76]. The terms are often used as synonyms, both colloquially and in the scientific 
literature [77]. In clinical interviews, patients with hypersomnolence often use the term 
fatigue to describe their symptoms of excessive daytime sleepiness [78]. One particular study 
showed that patients with narcolepsy and patients with insomnia both scored high on the FSS 
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when asked for symptoms of fatigue. However, only narcoleptic patients reported sleepiness 
as an increased propensity to fall asleep during the day assessed by the ESS [79]. In insomnia 
research, it is well established to differentiate between both concepts as clinical criteria, as 
patients with primary insomnia complain about excessive fatigue during the day, but not 
about sleepiness as defined above [80]. Because the meaning of both terms differs between 
languages, the assessment of fatigue and sleepiness is even more difficult. This is especially 
true for the FSS, which uses the term “fatigue” without any further specifications. 
There is converging evidence that fatigue and sleepiness are two different concepts with a 
limited overlap of symptoms. Because fatigue is mostly poorly defined, applied assessment 
tools are often not precise enough to distinguish between both conditions [81]. Few original 
studies on MS (e.g. [27, 46]) have explicitly distinguished between the concepts of sleepiness 
and fatigue and have explored the relationship between both clinical conditions in more detail. 
In many other studies, the terms fatigue and sleepiness are used inconsistently, sometimes 
even synonymously [76]. In general, the terms fatigue, tiredness and sleepiness are rarely 
explored differentially, and their lack of distinction is a major issue in clinical research and 
practice [21].  
The impact of sleep disorders 
Fatigue in MS appears to be multifactorial, with a component of fatigue directly attributable 
to the MS disease process (primary fatigue), as well as to secondary chronic illness factors, 
such as pain, medication, depression or other comorbidities, including poor sleep [4, 82, 83]. 
It has been reported that at least 50 % of patients with MS complain about sleep disturbances 
or poor sleep [5, 84]) Recent studies suggest that primary sleep disorders may intensify MS-
related fatigue [31, 85]. In addition, patients with MS are at an increased risk of secondary or 
comorbid forms of insomnia because common symptoms of MS (e.g. nocturia, pain, 
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spasticity, paraesthesias, depression, and anxiety) often interfere with restorative sleep. 
Specific sleep disorders such as RLS, PLMD, and SRBD have also been reported to be 
present at higher frequencies in MS patients than in the general population [4, 6, 33, 86]. 
Comorbid sleep disorders and poor sleep are often unrecognized clinical conditions in MS and 
may additionally contribute to fatigue [29, 87]. This notion is supported by the findings that 
treatment of different sleep disorders, particularly SRBD, is effective to reduce fatigue in MS 
[61, 64, 73]. 
The largest study included in our review comprised 2,375 MS patients and focused on the 
frequency of sleep disorders and their association with fatigue and sleepiness [31]. As 
assessed by the ESS, the prevalence of daytime sleepiness was reported to be 30%, while that 
for abnormal fatigue measures was 60%. Increased sleepiness and fatigue scores were 
associated with positive screenings for insomnia, SRBD, and RLS that showed prevalence 
rates of 32%, 38%, and 37%, respectively. Thus, more than 70% of this large MS cohort 
screened positive for at least one or more sleep disorders [31]. Studies using sleep 
questionnaires, actigraphy or PSG found a positive correlation between subjectively or 
objectively measured disrupted sleep and fatigue in MS patients [26, 27, 40, 48, 56, 61]. 
Kaynak and colleagues [41] found that the total arousal index was higher in a subgroup of 
fatigued patients compared to a non-fatigued group. However, another polysomnographic 
study investigating sleep-related correlates of fatigue in MS, reported conflicting results [36]. 
In the case of increased daytime sleepiness, sleep disorders associated with hypersomnolence 
may be highly prevalent, yet underrecognized, clinical conditions in MS contributing to 
increased fatigue [29].  
Methodological constraints 
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Our systematic review provides a qualitative and descriptive survey of the summarized 
studies that include original data. We may have failed to identify all relevant studies as the 
ESS might not be mentioned in the fields available via the databases’ search interfaces. There 
was noticeable heterogeneity between studies with respect to study design, experimental 
procedures, and the quality of data sets on ESS or FSS. Therefore, no meta-analysis of effect 
sizes regarding sleepiness or fatigue scores was feasible for this review. As an operational 
definition of daytime sleepiness, we used sleep propensity as assessed by the ESS. However, 
the ESS is a subjective rating of sleep propensity in daily life and covers only one specific 
aspect of the multi-dimensional concept of sleepiness [88]. In addition, even though the ESS 
is widely used as an assessment tool in clinical practice and research, this instrument has only 
modest psychometric properties. The reliability and validity of the ESS as a unidimensional 
scale for sleepiness has been questioned by a number of studies [89]. However, due to the 
huge body of findings on the ESS and the knowledge of its strengths and limitations, utilizing 
the ESS as an assessment tool for evaluating sleepiness in MS seems to be an appropriate 
approach. Studies on MS comparing subjective and objective measures of sleepiness (e.g. 
multiple sleep latency test, maintenance of wakefulness test, or pupillography sleepiness test) 
are rare [27, 40, 41, 49, 90] and beyond the scope of our review but warrant further research. 
Implications for clinical practice 
Sleepiness may confound measures developed to assess fatigue (see also Table 1). In general, 
individuals seem to subsume sleepiness under the broader notion of being tired or feeling 
fatigued. Thus, if patients with MS present fatigue as chief complaints or score high on 
fatigue scales, clinicians should be aware of the heterogeneity of the various symptoms. To 
evaluate sleepiness and fatigue in MS as two distinct clinical conditions, we suggest the 
following approach. presented in a basic flow chart (Figure 2). 
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--- Insert Figure 2 about here --- 
Firstly, MS patients with complaints of fatigue should be evaluated with regard to the severity 
and clinical significance of the symptoms (e.g. by using the FSS, the MFIS or other rating 
scales on the impact of fatigue). Secondly, sleepiness should be evaluated by the assessment 
of clinical signs of daytime sleepiness and supplemented by the use of the ESS. Increased 
daytime sleepiness may be indicative of sleep disorders associated with hypersomnolence and 
call for specific diagnostic procedures (ICSD-3). However, hypersomnolence can also be due 
to insufficient sleep caused by a lack of sleep hygiene or habitual short sleep times. Even if 
there are no signs of elevated sleep propensity during the day (i.e. ESS ≤ 10), MS patients 
may complain about fatigue due to poor sleep or sleep disturbances, which are highly 
prevalent in MS [5, 84]. Thus, overall fatigue or tiredness, but not sleepiness, is a core 
daytime symptom of insomnia that can perpetuate MS-related fatigue similarly to depression 
[38, 55, 56]. As mentioned above, sleep disturbances and poor sleep are common in MS and 
may contribute significantly to daytime fatigue. 
Veauthier & Paul suggested that MS patients with fatigue (e.g. MFIS > 34) and impaired 
sleep quality (e.g. Pittsburgh sleep quality index (PSQI) > 5) should undergo further sleep 
evaluation and, if appropriate, sleep assessment in a sleep laboratory using PSG (e.g. to 
distinguish between pain, spasticity, and RLS) [6]. In cases of increased fatigue or sleepiness 
or tiredness associated with poor sleep non-restorative sleep, sleep disturbances observed by 
others (e.g. heavy snoring, apneas, leg movements) or impaired daytime functioning, MS 
patients should also be evaluated regarding sufficient sleep quantity and symptoms of specific 
sleep disorders such as RLS, PLMD, SRBD, or insomnia. Diagnosed sleep disorders have to 
be treated by sleep experts accordingly. The use of medications causing sedation or 
hypersomnia, as well as comorbid somatic or psychiatric disorders such as depression and 
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anxiety, also needs to be taken into account. Patients with symptomatic sleepiness may 
particularly benefit from wakefulness-promoting agents, activity, or daytime naps but not 
from rest [21]. If clinically significant fatigue is primary and intrinsic to the MS pathology, 
therapy should focus on fatigue-specific treatment such as energy conservation programs, 
cooling therapy or cognitive-behavioral therapy [71, 91, 92].  
Conclusions 
Given the high but often underestimated prevalence of disturbed sleep in MS, patients with 
MS who suffer from fatigue that affects daily functioning should undergo a sleep evaluation if 
there are any signs of poor or non-restorative sleep. Within the prominent complaint of 
fatigue, sleepiness as a distinctive symptom can be easily overlooked. If patients with MS 
report fatigue or tiredness, specific aspects of unintentional sleep or the propensity to fall 
asleep should be assessed. In this context, the ESS, as a short and easy-to-administer 
questionnaire, may be used as an additional assessment tool. The presence of daytime 
sleepiness can guide diagnostic evaluations with respect to comorbid sleep disorders 
associated with hypersomnolence, allowing potential treatment by effective countermeasures 
of sleepiness (e.g. wakefulness-promoting agents; avoidance of monotony, utilizing power 
naps, no rest). 
Although sleepiness seems to be less prevalent and less severe than fatigue, it is present in a 
substantial number of patients with MS. Yet, sleepiness and tiredness-related fatigue due to 
sleep disturbances are both underrecognized and undertreated clinical conditions in MS that 
are in need of specific diagnoses and appropriate treatments. 
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Practice points 
• Sleepiness and fatigue are two interrelated, albeit distinct concepts with limited 
overlap.  
• In patients with MS, fatigue is more prevalent and severe than daytime sleepiness.  
• Fatigue without sleepiness is frequent in MS, whereas sleepiness without fatigue is 
rare. 
• High scores on fatigue scales are often accompanied by increased daytime 
sleepiness. Therefore, the ESS should also be applied in MS patients with 
increased fatigue scores. Both clinical conditions may be associated with sleep 
disorders. 
• Increased sleepiness, as well as significant complaints of fatigue and poor sleep, 
warrants further assessment of potential comorbid sleep disorders or negative 
effects of hypnotic use. Elevated ESS scores may be indicative of sleep disorders 
associated with hypersomnolence and demand specific treatment of daytime 
sleepiness. 
• The clinical significance of daytime sleepiness in MS patients remains unknown; 
nevertheless it may be presumed that it diminishes the quality of life of the 
patients. 
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Research agenda 
• The assessment of the prevalence of daytime sleepiness in MS is needed. This 
requires a systematic epidemiological study using the ESS or other questionnaires 
in a large population of patients with MS focusing on the assessment of daytime 
sleepiness as the inability to stay awake and alert. 
• Cross-sectional studies on distinct subtypes of MS should take into account both 
concepts of fatigue and sleepiness, using adequate and established assessment 
tools for each condition.  
• Longitudinal studies are necessary to clarify whether the course of MS is related to 
the development of fatigue, sleepiness or sleep disorders. 
• Prospective studies following MS patients with different subtypes should be 
performed to allow for the analysis of the association between fatigue, sleepiness 
or potential sleep disorders and the clinical MS status of the patients including the 
severity of disability as well as MRI findings. 
• Studies comparing objective assessments of daytime sleepiness (e.g. maintenance 
of wakefulness test, pupillography, vigilance or sustained attention tasks) with 
subjective measures of sleepiness and fatigue are needed in patients with MS 
• In MS, systematic studies using the ESS or other screening tools for 
hypersomnolence are needed. Abnormal findings should be validated using more 
specific assessments (e.g. polysomnography).  
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__________________________________________________________________________________ 
 
 
 
 
Figure legends 
Figure 1 Flow diagram of the study selection process 
Legend below figure: 
MS: multiple sclerosis; ESS: Epworth sleepiness scale 
Figure 2 Flow diagram of the diagnostic assessment of sleepiness and fatigue in multiple 
sclerosis (MS) 
Legend below figure: 
ESS: Epworth sleepiness scale; FSS: fatigue severity scale; MFIS: modified fatigue impact 
scale; PSG: polysomnography; PSQI: Pittsburgh sleep quality index 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1 Comparison of fatigue and sleepiness as two different domains 
  
 Fatigue Sleepiness 
Definition 
“Fatigue is a subjective lack of physical and/or mental energy that is 
perceived by the individual or the caregiver to interfere with usual and 
desired activities.” (p. 2) [82] 
 “Sleepiness is the inability to stay awake and alert during 
the major waking episodes of the day, resulting in periods of 
irrepressible need for sleep or unintended lapses into 
drowsiness or sleep.” (p. 143) [18] 
Symptoms • Feelings of tiredness, exhaustion, weariness or lassitude  
• not necessarily associated with sleep pressure 
• no definite sleep drive when resting (e.g. lying down to relax) 
• Decreased level of alertness or wakefulness 
• increased tendency to fall asleep or doze off 
unintentionally  
• sleep drive when resting (e.g. lying down to nap) 
Semantics • Tiredness is commonly used as synonym (e.g. by insomniacs) • Tiredness is commonly used as synonym (e.g. by 
narcoleptics) 
Characteristics 
in MS 
• Common and most troublesome symptom  
• strong negative impact on social and occupational functioning  
• Not commonly associated with MS 
• often associated with sleep disorders 
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Table 1 continued  
 
Assessment  
by common 
rating scales 
Fatigue severity scale (FSS)  
- most widely used validated scale 
- evaluates the impact on motivation, physical abilities and  
  social functioning 
- self-administered, 9 items 
- 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree)  
- critical cut-off: mean FSS score >4 (min: 1; max: 7)  
  or total FSS score ≥36 (min: 9; max: 63) 
Epworth sleepiness scale (ESS) 
- most commonly used scale in sleep research and clinical 
settings 
- assessment of sleep propensity 
- self-administered, 8-item questionnaire 
- 4-point Likert scale (from 0 to 3) to rate the likelihood 
   of dozing off in eight everyday situations 
- critical cut-off: total ESS score  >10 (min: 0; max: 24) 
Objective 
assessments 
• No validated measures available 
 
• Maintenance of wakefulness test; multiple sleep latency 
test; EEG; pupillography 
• psychomotor vigilance task; sustained attention and 
vigilance tasks; driving simulator 
Counter-
measures 
• Alleviated by periods of rest, unlike weakness (asthenia) 
• limited efficacy of stimulants  
• Most effective: sleep or short naps, but not rest  
• stimulants temporarily effective 
  
EEG: electroencephalography; ESS: Epworth sleepiness scale; FSS: fatigue severity scale; MS: multiple sclerosis 
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Table 2 Summarized studies using the Epworth sleepiness scale (ESS) as an assessment tool in patients with multiple sclerosis (MS) – cross-sectional studies 
Authors, year 
[reference]  
N MS-
patients 
(n controls) 
N MS-patients 
 in subgroups 
Age  
mean (SD) 
median* 
[range] 
Sex 
female 
% 
ESS 
mean (SD)  
median* 
[range] 
ESS  
>10 
(%) 
Fatigue score 
mean (SD) 
 median* 
[range] 
Significant 
correlation  
ESS x fatigue 
score 
Study 
design 
 
Main outcome 
Attarian et al. 
2004 [26] 
 
30 (15) 
 
 
15 fatigue 
15 non-fatigue 
46.4 (-) 
33.5 (-) 
73% 
total 
12* [2-24] 
5* [0-19] 
60% 
13% 
7* [5-11] 
3* [1-4] 
r not reported 
p=.02 
CS 
CC 
Significant correlation between fatigue and disrupted 
sleep/abnormal sleep cycles in MS assessed by 
actigraphy. 
Beran et al. 
2008 [27] 
12 (14) 
 
6 sleepiness 
6 non-sleepiness 
47.8 (-) 
total 
83% 
total 
15.0 (4.4) 
4.8 (3.1) 
- 
- 
5.1 (1.7) 
3.4 (1.4) 
- 
 
CSPSG 
CC 
Significant relationship between PLMS with arousals 
and increased sleepiness 
Braley et al.+ 
2012 [28] 
30 (30) 
 
Total 46.7 (11.3) 70% 11.3 (4.9) - - n.s.  CSPSG 
CC 
Fatigue, tiredness, and lack of energy, but not 
sleepiness, are more frequent in MS compared to 
controls.  
Braley et al. 
2014 [29] 
195 Total 
110 elevated OSA risk 
85 no elevated OSA risk 
154 OSA not confirmed 
41 diagnosed OSA 
47.1 (12.1) 
50.3 (11.8) 
43.0 (11.1) 
45.8 (12.2) 
52.1 (10.4) 
66% 
53% 
82% 
68% 
59% 
8.1 (5.1) 
9.1 (5.0) 
6.9 (5.1) 
7.9 (5.0) 
9.0 (5.6) 
- 
- 
- 
- 
- 
4.6 (1.8) 
5.1 (1.6) 
4.0 (1.8) 
4.5 (1.8) 
5.0 (1.6) 
FSS  
r=.44; p<.0001 
 
CS 
CC 
Sleep disturbances, especially OSA, are frequent in MS 
and may contribute to fatigue..  
Braley et al. 
2015 [30] 
190 Total 
121 fatigue 
69 non-fatigue 
47.0 (12.2) 
47.6 (11.5) 
46.4 (13.3) 
67% 
65% 
71% 
8.2 (5.1) 
9.4 (5.3) 
5.8 (4.0) 
- 
- 
- 
4.6 (1.8) 
5.7 (0.9) 
2.5 (0.8) 
- CS 
 
47% of MS patients use hypnotics; carry-over effects 
may be involved in fatigue 
Brass et al. 
2014 [31] 
2375 Total 54.7 (12.4) 81% 8* [0-24] 30% 45* [6-63] - CS The majority of MS patients are affected by one or 
more sleep disorders, often undiagnosed.  
Bøe Lunde et al.+ 
2012 [32] 
 
90 (108) Total (73 with valid ESS) 
24 good sleepers 
49 poor sleepers 
45.0 (10.4) 
43.2 (12.0) 
46.2 (10.4) 
54% 
38% 
65% 
8.6 (4.6) 
- 
- 
34% 
22% 
42% 
- 
- 
- 
- 
 
CS 
CC 
Poor sleep is common in MS. Treatment may improve 
sleep and quality of life. 
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Table 2 continued (2) – cross-sectional studies 
Authors, year 
[reference]  
 
N MS-
patients 
(n controls) 
N MS-patients 
 in subgroups 
Age  
mean (SD) 
median* 
[range] 
Sex 
female 
% 
ESS 
mean (SD)  
median* 
[range] 
ESS  
>10 
(%) 
Fatigue score 
mean (SD) 
 median* 
[range] 
Significant 
correlation  
ESS x fatigue 
score 
Study 
design 
 
Main outcome 
Chen et al. 
2014 [33] 
21 (11) 11 fatigue 
10 non-fatigue 
30.9 (11.0) 
26.8 (4.1) 
73% 
70% 
15.7 (7.2) 
9.0 (2.8) 
38% 
- 
50.8 (6.1) 
26.1 (6.4) 
FSS 
r=.74; p<.001 
CSPSG 
CC 
Sleep disorders and excessive daytime sleepiness are 
more common in MS. 
Constantinescu et al. 
2011 [34] 
34  24 valid ESS data 41.5**  
[36-49] 
58% 10**  
[5.3-14.5] 
- 5.4 **  
[4.4-6.1] 
FSS 
r=.47; p=.019 
CS 
CC 
No evidence of orexin A deficiency in MS but in other 
CNS inflammatory diseases 
Dias et al.  
2012 [35] 
103 Total 45.8 (11.0) 72% 7.3 (4.8) 23% 4.6 (1.6) FSS 
r=.31; p<.01 
CS Over 40% of MS patients show elevated OSA risk. 
Elkattan et al. 
2009 [36] 
20 (10) 10 fatigue 
10 non-fatigue 
27.7 (6.5) 
28.8 (6.7) 
- 
- 
7.2 (4.0) 
5.3 (4.2) 
- 
- 
27.7 (6.5)¹ 
28.8 (6.7)¹ 
- CSPSG 
CC 
Sleep parameters do not distinguish between fatigued 
and non-fatigued MS patient.s 
Frauscher et al. 
2005 [37] 
61( 42) Total 34.5 (8.3) 
 
53% 7.4 (3.5) 26% - - CS 
CC 
No increased daytime sleepiness in MS compared to 
controls 
Ghajarzadeh et al.  
2012 [38] 
100 64 fatigue 
36 non-fatigue 
34.0 (8.4) 
28.4 (8.3) 
73% 
78% 
3.8 (3.1) 
3.6 (3.1) 
6% 
6% 
35.3 (17.6)°5 
19.1 (16.5)°5 
MFIS 
r=.33; p=.001 
CS Significant correlations between fatigue scores and 
depression, sleep quality, and ESS  
Heesen et al. 
2006 [39] 
30 15 fatigue 
15 non-fatigue 
46.6 (11.7) 
42.9 (10.2) 
60% 
60% 
10.5 (4.7) 
3.3 (2.4) 
- 
- 
6.1 (0.7) 
1.5 (0.7) 
- CS Fatigue in MS may be influenced by increased levels of 
inflammatory cytokines.  
Kaminska et al. 
2012 [40] 
62 (32) Total 47.3 (10.4) 73% 8.4 (4.4) 34% 5.1 (1.6) FSS 
r=.31; p=.002 
CSPSG 
CC 
OSA is common in MS and related to fatigue, but not to 
sleepiness. 
Kaynak et al. 
2006 [41] 
37 (13) 27 fatigue 
10 non-fatigue 
37.4 (8.7) 
36.5 (8.4) 
59% 
50% 
4.4 (2.8) 
3.3 (3.0) 
7% 
0% 
5.5 (0.9) 
< 4 
n.s. CSPSG 
 
Sleep fragmentation observed in MS patients can be 
involved in MS fatigue. 
Kister et al. 
2010 [42] 
167 94 migraineurs 
73 no headache 
43 (11.0) 
47 (13.0) 
90% 
57% 
8.1 (-) 
5.6 (-) 
- 
- 
5.0 (-) 
3.6 (-) 
- CS Migraine in MS is more frequent than in the general 
population. 
Knudsen et al.  
2008 [43] 
48 MS  
and MON 
Total 
 
- [21-57] 71% 
 
5.6 (2.9) 
 
10% 
 
- - CS Intact hypocretin system in both subgroups, no 
increased sleepiness  
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Table 2 continued (3) – cross-sectional studies 
Authors, year 
[reference] 
N MS-
patients 
(n controls) 
N MS-patients 
 in subgroups 
Age  
mean (SD) 
median* 
[range] 
Sex 
female 
% 
ESS 
mean (SD)  
median* 
[range] 
ESS  
>10 
(%) 
Fatigue score 
mean (SD) 
 median* 
[range] 
Significant 
correlation  
ESS x fatigue 
score 
Study 
design 
Main outcome 
Kotterba et al.  
2003 [44] 
31 Total 35.6 (8.3) 58% 6.1 (2.9) 10% 4.3 (1.6) FSS 
r=.42; p<.05 
CS Terms ”sleepiness” and “fatigue” are often confused, 
but different scales allow for differentiation  
Labuz-Roszak et al. 
2012 [45] 
122 Total 37.7 (10.8) 71% 6.3 (3.9) 21% 40.6 (14.8)¹ FSS 
r=.18; p=.03 
CS Fatigue is frequent in MS and moderately correlated 
with depression and anxiety.  
Merkelbach et al. 
2011 [46] 
80 Total 43.2 (9.8) 71% 8.1 (3.7) - 4.4 (1.6) FSS 
r=0.42; p<0.001 
CS Physical activity correlates with disease severity, but 
not with fatigue or sleepiness. 
Mills and Young+ 
2011 [47] 
635  559 valid ESS data 46.6 (10.9) 71% 7.9 (4.5) - - n.s. CS Fatigue is correlated with disability, disease type and 
sleep duration (u-shaped correlation). 
Moreira et al. 
2008 [48] 
44 32 RLS 
12 non-RLS 
40.7 (14.8) 
44.1 (13.4) 
67% 
75% 
5.7 (4.0) 
5.7 (3.0) 
7% 
total 
- 
- 
n.s. CS MS patients with RLS show greater disability, poorer 
sleep and increased levels of fatigue. 
Neau et al. 
2012 [49] 
205 
25 with PSG 
Total questionnaire 
8 fatigue + sleepiness 
17 fatigue, non-sleepiness 
43.7 (11.1)  
40.1 (11.2) 
39.7 (9.3) 
76% 
63% 
59% 
7.3 (4.8) 
14.7 (0.5) 
4.6 (2.1) 
31% 
- 
- 
81.6 (34.2)°3 
118.2 (23.8)°3 
65.6 (33.1)°3 
FIS 
r=.68 subgroups 
p<.0001 
CSPSG 
 
Sleep disturbances and excessive daytime sleepiness are 
frequent in MS.  
Neumann et al. 
2014 [50] 
35 (15) 30 fatigue 
5 non-fatigue 
44.7 (7.1) 
45.3 (6.1) 
73% 
40% 
8.2 (2.1) 
5.4 (3.0) 
0%x 
-
 
75.6 (13.5)°4 
49.4 (10.6)°4 
- CS Reaction time is an objective marker for fatigability. 
Niepel et al.+ 
2013 [51] 
26 (9) Total 
17 fatigue 
9 non-fatigue 
- 
49.4 (9.2) 
41.8 (13.1) 
65% 
71% 
56% 
5.6 (4.1) 
7.0 (3.8) 
3.0 (3.7) 
15% 
- 
- 
- 
- 
- 
r=0.41 
p=0.039 in 
fatigued patients 
CS 
CC 
Fatigued MS patients have reduced levels of alertness 
and sympathetic activity. Modafinil shows alerting and 
sympathomimetic short-term effects. 
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Table 2 continued (4) – cross-sectional studies 
Authors, year 
[reference] 
 
N MS-
patients 
(n controls) 
N MS-patients 
 in subgroups 
Age  
mean (SD) 
median* 
[range] 
Sex 
female 
% 
ESS 
mean (SD)  
median* 
[range] 
ESS  
>10 
(%) 
Fatigue score 
mean (SD) 
 median* 
[range] 
Significant 
correlation  
ESS x fatigue 
score 
Study 
design 
Main outcome 
Papuc et al. 
2010 [52] 
38 (15) Total 
10 fatigue 
28 non-fatigue 
36* [21-68] 
34* [21-69] 
38* [22-55] 
53% 
54% 
60% 
6* [2-11] 
6* [2-11] 
6* [4-8] 
- 
- 
- 
5.5* [1.7-6.6] 
5.7* [4.8-6.6] 
2.6* [1.7-4.1] 
- CS 
CC 
CSF hypocretin-1 levels do not differ between MS and 
controls, but are correlated with fatigue levels.  
Pokryszko-Dragan et al.  
2013 [53] 
100 Total 
49 fatigue 
51 non-fatigue 
42 [20-67] 
- 
- 
69% 
- 
- 
6.3 [0-19] 
6.4 (3.9) 
6.2 (4.7) 
19% 
- 
- 
3.8 [1.1-7.0] 
- 
- 
n.s. CS Sleep disturbances may increases fatigue and are related 
to MS symptoms and therapies. 
Sauter 
2004 [54] 
30  Total 40.4 (9.2) 67% 9.7 (4.2) 13% 5.2 (1.1) n.s. CS 
CC 
MS patients differ from controls in sleep efficiency, 
sleep quality, and quality of life.  
Stanton et al.  
2006 [55] 
60 Total 41* [19-69] 72% 7 * [0-19] 32% 11* [2.5-15.8] FSS 
r=.30; p=.022 
CS Sleep disturbances are frequent in MS and may 
contribute to fatigue. 
Veauthier et al. 
2011 [56] 
(2013) [73] 
 
141 66 PSG total 
   26 fatigue 
   40 non-fatigue 
75 no PSG total 
    21 fatigue 
   54 non-fatigue 
43.2 (10.0) 
45.3 (9.5) 
42.0 (10.2) 
45.4 (10.8) 
44.5 (10.6) 
45.9 (10.9) 
68% 
73% 
65% 
67% 
55% 
72% 
8.9 (4.7) 
11.3 (4.2) 
7.5 (4.5) 
8.2 (4.6) 
9.8 (4.4) 
7.6 (4.5) 
- 
- 
- 
- 
- 
- 
4.5 (1.8) 
6.0 (1.0) 
3.6 (1.6) 
4.8 (1.7) 
5.9 (1.0) 
4.4 (1.7) 
- 
 
CSPSG Significant relationship between sleep disorders and 
fatigue in MS  
Wunderlin et al.  
1997 [57] 
10 Total 45.0 (8.0) 80% 9.2 (5.3) 40% 4.5 (1.7) - CS Fatigue and daytime sleepiness cannot be explained by 
nocturnal apneas or oxygen desaturations. 
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Table 2 continued (5) – cross-sectional data of longitudinal studies 
Authors, year 
[reference] 
N MS-
patients 
(n controls) 
N MS-patients 
 in subgroups 
Age  
mean (SD) 
median* 
[range] 
Sex 
female 
% 
ESS 
mean (SD)  
median* 
[range] 
ESS  
>10 
(%) 
Fatigue score 
mean (SD) 
 median* 
[range] 
Significant 
correlation  
ESS x fatigue 
score 
Study 
design 
Main outcome 
Attarian et al. 
2011 [58] 
29 15 placebo 
14 eszopiclone 
46.5 [31-58] 
45.0 [25-64] 
80% 
87% 
12.5 (4.3) 
9.9 (3.6) 
- 
- 
11.1 (2.2)°2 
7.9 (2.8)°2 
- LS 
CC, PC 
Eszopiclone increases total sleep time, but does not 
improve fatigue in MS.  
Brioschi et al.  
2009 [59] 
12 Total 43.3 (9.3) 92% 9.3 (3.9) - 5.6 (0.9)°1 - LS Modafinil improves fatigue in MS, no changes in 
physical activity 
Bruce et al. 
2012 [60] 
30 16 after placebo (phase I) 
14 after placebo (phase II) 
49.9 (7.2) 
47.7 (6.0) 
88% 
79% 
9.3 (4.3) 
9.7 (5.0) 
- 
- 
18.6 (10.2)°5 
17.8 (8.4)°5 
- LS 
PC 
Armodafinil improves delayed verbal recall, no other 
changes in other outcome parameters. 
Côté et al. 
2013 [61] 
62 21 SLD treated 
18 SLD untreated 
17 no SLD 
51.3 (8.3) 
49.8 (8.8) 
41.9 (10.7) 
62% 
78% 
77% 
9.6 (3.8) 
7.6 (4.9) 
7.9 (4.8) 
- 
- 
- 
5.1 (1.6) 
5.4 (1.5) 
4.8 (1.8) 
- LSPSG 
 
Treatment of OSA and RLS improves fatigue in MS. 
 
García Jalón et al. 
2013 [62] 
23 10 MS control 
13 MS intervention 
52.0 (7.0) 
45.9 (9.9) 
60% 
77% 
12.4 (4.5) 
6.9 (4.1) 
- 
- 
5.9 (0.9) 
5.6 (0.6) 
- LS 
 
High acceptance of an energy conservation program 
by MS patients 
Gerhard 
2009 [63] 
30 Total 36.0 (10.4) 67% 8.4 (3.7) 37% 35.2 (16.9)¹ - LS IFN1β1a treatment increases fatigue, and improves 
cognitive functions. 
Kallweit et al. 
2013 [64] 
69 Total 
28 SRBD 
41 non-SRBD 
49.8 (9.2) 
53.3 (9.5) 
47.4 (8.3) 
70% 
57% 
78% 
- 
9.7 (3.8) 
9.4 (4.7) 
- 
61% 
44% 
- 
5.5 (0.9) 
5.7 (0.7) 
- LS High prevalence of SRBD in MS patients; continuous 
positive airway pressure therapy decreases fatigue but 
not sleepiness. 
Mendozzi et al. 
2010 [65] 
 
42 Total 
12 no-IMA 
10 glatiramer acetate 
10 IFN1β1a/b s.c. 
10 IFN1β1a/b i.m.. 
39.4 (7.4) 
41.8 (5.7) 
38.6 (8.4) 
38.5 (9.9) 
38.2 (5.4) 
- 
- 
- 
- 
- 
5.7 (3.2) 
6.3 (3.6) 
6.8 (2.5) 
4.8 (2.7) 
4.9 (3.6) 
14% 
- 
- 
- 
- 
3.6 (1.8) 
3.4 (1.6) 
4.4 (1.7) 
4.1 (1.9) 
2.7 (1.6) 
- LS 
 
IFNβ and glatiramer acetate treatment decrease sleep 
efficiency in MS assessed by actigraphy 
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Table 2 continued (6) – cross-sectional data of longitudinal studies 
Authors, year 
[reference] 
N MS-
patients 
(n controls) 
N MS-patients 
 in subgroups 
Age  
mean (SD) 
median* 
[range] 
Sex 
female 
% 
ESS 
mean (SD)  
median* 
[range] 
ESS  
>10 
(%) 
Fatigue score 
mean (SD) 
 median* 
[range] 
Significant 
correlation  
ESS x fatigue 
score 
Study 
design 
Main outcome 
Möller et al.  
2011 [66] 
121 59 placebo 
62 modafinil 
40.8 (11.2) 
41.4 (9.5) 
78% 
63% 
11.8 (5.0) 
11.8 (4.9) 
- 
- 
5.8 (0.8) 
6.0 (0.8) 
- LS 
PC 
No effect of modafinil on fatigue in MS 
 
Rammohan et al.  
2002 [67] 
72 Total 44.0 [23 -61] 75% 9.5 [1-20] - 5.9 [4-7] - LS 
PC 
Modafinil significantly improves fatigue.  
Stankoff et al.  
2005 [68] 
115  59 placebo 
56 modafinil 
44.0 (9.0) 
43.8 (8.0) 
- 
- 
9.7 (5.5) 
10.6 (4.8) 
53% 
total 
63.1 (9.3)°5 
63.3 (10.0)°5 
- LS 
PC 
No differences between effects of modafinil and 
placebo treatment on fatigue in MS  
Svenningsson et al.  
2013 [69] 
195  Total  39.7 (9.2) 71% 8.8 (-) - 71.2 (-)°4 - LS Natalizumab improves fatigue, sleepiness, quality of 
life, depression, and cognition.  
Vakhapova et al. 
2010 [70] 
16 Total 45.4 [26-60] 
 
- 
 
6.4 (5.6) 
 after placebo 
- 
 
37.4 (15.8)1  
after placebo 
- LS 
PC 
Sublingual tizanidine improves daytime sleepiness and 
spasticity in MS 
Van Kessel et al.+ 
2008 [71] 
72 35 CBT 
37 relaxation training 
42.9 (9.3) 
47.0 (9.5) 
80% 
70% 
6* [-] 
5* [-] 
- 
- 
20.91 (4.3) 
20.31 (4.3) 
- LS 
CC 
Both CBT and relaxation training are effective 
treatments for fatigue in MS; CBT is more effective. 
Zifko et al.  
2002 [72] 
50 Total 40.4 (10.3) 60% 9.7 (3.9) - 30.3 (8.5)¹ - LS Modafinil treatment improves fatigue and sleepiness 
in MS. 
 
Symbols: *median; ** median [interquartile range]; ~ longitudinal study; + data provided on request; PSG use of PSG; x ESS score >10 exclusion criterion; - data not reported  
 
Statistics: F/non-F: subdivision in fatigued and non-fatigued subgroups; n: number of participants; n.s.: not significant; p: p-value; r: correlation coefficient; SD: standard deviation  
 
Fatigue Scales: FSS: fatigue severity scale (cut off >4); 1 FSS total score (cut off >36) 
 
Other Fatigue Scales: °1 FAI: fatigue assessment inventory (cut off ≥4); °2 FDS: fatigue descriptive scale (cut off >5); °3 FIS: fatigue impact scale; °4 FSMC: fatigue scale for motor and cognitive functions (mild fatigue 
≥43; moderate fatigue ≥53; severe fatigue ≥63); °5 MFIS: modified fatigue impact scale (cut off >34)  
 
CBT: cognitive behavioral therapy; CC: case-controlled; CS: cross-sectional study; IFN1β1a/b s.c.: interferon-beta 1a or interferon-beta 1b for subcutaneous injection; IFN1β1a/b i.m.: interferon-beta 1a or interferon-beta 
1b injected intramuscularly; LS: longitudinal study; MON: monosymptomatic optic neuritis; no-IMA: no treatment with immunomodulant agents; OSA: obstructive sleep apnea; PC: placebo-controlled; PLMS: periodic 
limb movements in sleep; PSG: polysomnography; RLS: restless legs syndrome; SRBD: sleep-related breathing disorder; SLD: sleep disorders  
 
Boldfaced numerals numerics denote scores above critical cut offs (e.g. ESS >10; FSS >4); Italic printed numerals numerics mark fatigue scores other than FSS score 
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Table 3 Additional information on longitudinal studies using the Epworth sleepiness scale (ESS) as an assessment tool in patients with multiple sclerosis (MS) 
Authors, year 
[reference] 
N 
MS-patients 
ESS 
baseline 
mean (SD) 
median* 
[range] 
ESS 
follow-up / 
intervention 
mean (SD) / 
median* 
[range] 
Fatigue 
baseline 
mean (SD) 
Fatigue 
follow-up/ 
intervention 
mean (SD) 
Follow-up period 
to baseline 
Intervention Intervention efficacy  
Attarian et al. 
2011 [58] 
15 placebo  
14 eszopiclone 
12.5 (4.3) 
9.9 (3.6) 
10.5 (3.9) 
8.2 (4.0) 
11.1°2 (2.2) 
7.9°2 (2.8) 
5.4°2 (3.1) 
4.6°2 (3.6) 
7 weeks Eszopiclone 
or placebo  
n.s. ESS and FSS changes  
Brioschi et al. 
2009 [59] 
12 9.3 (-) T1: 9.1 (3.0) 
T2: 10.4 (4.7) 
5.6°1 (0.9) T1: 4.5°1 (1.1) 
T2: 5.1°1 (1.1) 
T1: 3 months with modafinil 
T2: 1 month without modafinil 
Modafinil n.s. ESS changes; 
significant FAI improvements T0 to T1 (∆1.1) 
Bruce et al. 
2012 [60] 
16 placebo first  
14 armodafinil first  
9.3 (4.3) 
9.7 (5.0) 
9.2 (5.0) 
10.5 (4.3) 
18.6°5 (10.2) 
17.8°5 (8.4) 
18.2°5 (10.6) 
18.6°5 (10.5)  
1 week change, 
(cross-over design) 
Armodafinil n.s. ESS and FSS changes  
 
Côté et al. 
2013 [61] 
21 SLD, treated 
18 SLD, untreated 
17 no SLD 
9.6 (3.8) 
7.6 (4.9) 
7.9 (4.8) 
6.1 (3.8) 
7.1 (5.5) 
7.2 (4.2) 
5.1 (1.6) 
5.4 (1.5) 
4.8 (1.8) 
4.5 (1.7) 
5.1 (1.5) 
5.2 (1.2) 
≥3 months Treatment of 
OSA and RLS  
Significant FSS (∆0.9), MFI°6, ESS and PSQI 
improvements 
García Jalón et al. 
2013 [62] 
10 MS control 
 
 
13 MS intervention 
12.4 (4.5) 
 
 
6.9 (4.1) 
T1: 10.2 (4.3) 
T2: 14.0 (10.7) 
T3: 10.6 (4.2) 
T1: 6.6 (4.2) 
T2: 6.5 (4.9) 
T3: 6.9 (4.1) 
5.9 (0.9) 
 
 
5.9 (0.6) 
T1: 4.9 (1.0) 
T2: 5.5 (0.9) 
T3: 4.9 (1.3) 
T1: 5.0 (1.4) 
T2: 4.7 (1.7) 
T3: 5.2 (1.3) 
T1: intervention 
T2: 6 weeks 
T3: 3 months 
Energy 
conservation 
program 
n.s. ESS, FSS and FIS changes; 
significant FIS Cognitive improvements  
(∆5.8) 
Gerhard 
2009 [63] 
30 8.4 (3.7) 10.2 (4.4) 35.2¹ (16.9) 38.8¹ (16.8) ≥6 months Interferon  Significant ESS (∆1.6) 
 and FSS (∆3.6) decline 
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Table 3 continued (2) 
Authors, year 
[reference]  
N 
MS-patients 
ESS 
baseline 
mean (SD) 
median* 
[range] 
ESS 
follow-up / 
intervention 
mean (SD) / 
median* 
[range] 
Fatigue 
baseline 
mean (SD) 
Fatigue 
follow-up/ 
intervention 
mean (SD) 
Follow-up period 
to baseline 
Intervention Intervention efficacy  
Kallweit et al. 
2013 [64] 
28 SRBD 
41 non-SRBD  
9.7 (3.8) 
9.4 (4.7) 
9.5 (3.0) 
- 
5.5 (0.9) 
5.7 (0.7) 
4.8 (0.6) 
- 
≥6 months OSA treatment n.s. ESS changes; 
significant FSS improvements (∆1.0) 
Mendozzi et al.  
2010 [65] 
 
 
42 total 
12 no-IMA  
10 GA 
10 IFN1β1a/b s.c.  
10 IFN1β1a/b i.m. 
5.7 (3.2) 
6.3 (3.6) 
6.8 (2.5) 
4.8 (2.7) 
4.9 (3.6) 
5.6 (3.9) 
6.4 (3.9) 
7.6 (3.6) 
4.8 (4.4) 
3.5 (2.5) 
3.6 (1.8) 
3.4 (1.6) 
4.4 (1.7) 
4.1 (1.9) 
2.7 (1.6) 
3.7 (1.7) 
3.5 (1.3) 
4.5 (1.9) 
4.0 (1.6) 
2.8 (1.6) 
≥ 7 nights No-IMA, GA, 
IFN1β1a/b s.c., 
IFN1β1a/b i.m. 
n.s. ESS and FSS changes 
Möller et al. 
2011 [66] 
62 modafinil  
59 placebo 
11.8 (4.9) 
11.8 (5.0) 
9.7 (4.4) 
9.5 (4.9) 
6.0 (0.8) 
5.8 (0.8) 
5.3 (1.2) 
5.4 (1.0) 
8 weeks Modafinil n.s. ESS, FSS and MFIS changes 
Rammohan et al.  
2002 [67] 
72 9.5 [1-20] T1: 7.2 (-) 
T2: 7.0 (-) 
        T3: - 
5.9 [4-7] T1: 4.7 (-) 
T2: 5.3 (-) 
T3: 5.3 (-) 
T1: 2 weeks 200 mg modafinil 
T2: 4 weeks (2 weeks 400 mg) 
T3: 7 weeks (3 weeks placebo  
       washout) 
Modafinil T1: significant ESS (∆2.3) and FSS (∆0.8) 
improvements;  
T2: significant ESS improvements (∆2.5); 
n.s. FSS changes  
Stankoff et al. 
2005 [68]  
56 modafinil 
59 placebo 
10.6 (4.8) 
9.7 (5.5) 
- 
- 
63.3°3 (10.0) 
63.1°3 (9.3) 
52.3°5 (18.5) 
49. 2°5 (16.6) 
35 days Modafinil Significant MFIS improvements for both 
groups (modafinil: ∆11.0 vs. placebo: ∆13.9), 
but no benefit of modafinil compared to 
placebo 
Svenningsson et al. 
2013 [69] 
143 8.8 (-) 7.5 (-) 
 
71.2°4 (-) 62.2°4 (-) 12 months Natalizumab  Significant ESS (∆1.33) and FSMC (∆9.0) 
improvements 
Vakhapova et al. 
2010 [70] 
16 6.4 (5.6) 
after  
placebo phase 
4.8 (4.6) s.l. 
5.5 (4.6) oral 
37.41 (15.8) 
after  
placebo phase 
33.61 (16.8) s.l. 
34.11 (17.0) oral 
7 days placebo phase and 
7 days of each condition  
(cross-over design) 
  Tizanidine 
 
Significant ESS improvements (∆1.6 only for 
s.l. application vs. placebo) 
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Table 3 continued (3) 
Authors, year 
[reference]  
N 
MS-patients 
ESS 
baseline 
mean (SD) 
median* 
[range] 
ESS 
follow-up / 
intervention 
mean (SD) / 
median* 
[range] 
Fatigue 
baseline 
mean (SD) 
Fatigue 
follow-up/ 
intervention 
mean (SD) 
Follow-up period 
to baseline 
Intervention Intervention efficacy  
Van Kessel et al.+ 
2008 [71] 
35 CBT 
 
 
37 relaxation training 
6* [-] 
 
 
5* [-] 
T1: 3* [-] 
T2: 3* [-] 
T3: 3* [-] 
T1: 6* [-] 
T2: 4* [-] 
T3: 4* [-] 
20.91 (4.3) 
 
 
20.31 (4.3) 
T1: 7.91 (4.3) 
T2: 9.01 (5.3) 
T3: 10.41 (6.4) 
T1: 11.61 (5.3) 
T2:11.11 (4.6) 
T3:12.51 (5.2) 
T1: 2 months (post treatment) 
T2: 5 months  
T3: 8 months  
CBT vs. 
relaxation 
training  
Significantly greater fatigue reductions in the 
CBT group across the 8 months compared to 
the relaxation training group  
Veauthier et al. 
2013 [73] 
58 total 
13 good compliance 
12 moderate compliance 
17 no compliance 
4 no feedback 
12 no sleep disorder 
9.1 (4.6) 
9.5 (5.9) 
9.8 (4.8) 
10.8 (3.7) 
6.0 (4.5) 
6.4 (2.9) 
8.5 (4.6) 
9.4 (5.9) 
9.3 (5.9) 
10.2 (2.9) 
6.8 (3.3) 
5.7 (2.5) 
4.7 (2.3) 
4.8 (1.1) 
5.5 (3.9) 
4.8 (1.7) 
4.9 (1.5) 
3.3 (1.5) 
4.0 (1.8) 
4.3 (1.5) 
3.9 (2.2) 
4.4 (1.7) 
3.2 (1.9) 
3.4 (1.6) 
16 months (median) 
 
Treatment of 
sleep disorders  
n.s. ESS changes; 
significant FSS improvements on in the entire 
cohort (∆0.7), but n.s. changes in subgroups;  
significant MFIS improvements in good 
compliance subgroup (∆15) 
 
Zifko et al. 
2002 [72] 
50 9.7 (3.9) 4.9 (2.9) 30.3¹ (8.5) 25.41 (3.7) 3 months  Modafinil Significant ESS (∆4.8) and FSS (∆4.9) 
improvement 
 
Statistics: n: number of participants; n.s.: not significant; SD: standard deviation; T1-3: times of assessment; ∆: changes; - data not reported 
Fatigue Scales: FSS: fatigue severity scale (cut off >4); 1 FSS total score (cut off >36) 
Other Fatigue Scales: °1 FAI: fatigue assessment inventory (cut off ≥ 4); °2 FDS: fatigue descriptive scale (cut off >5); °3 FIS: fatigue impact scale; °4 FSMC: fatigue scale for motor and cognitive functions (mild fatigue 
≥43; moderate fatigue ≥53; severe fatigue ≥63); °5 MFIS: modified fatigue impact scale (cut off >34/45); °6 MFI: multidimensional fatigue inventory 
CBT: cognitive behavioral therapy; GA: glatiramer acetate; IFN1β1a/b s.c.: interferon-beta 1a or interferon-beta 1b for subcutaneous injection; IFN1β1a/b i.n. interferon-beta 1a or interferon-beta 1b injected 
intramuscularly; no-IMA: no treatment with immunomodulant agents; OSA: obstructive sleep apnea; PSQI: Pittsburgh sleep quality index; RLS: restless legs syndrome; SRBD: sleep-related breathing disorder; SLD: sleep 
disorders; s.l.: sublingual  
Boldfaced numerals numerics denote scores above critical cut offs (e.g. ESS >10; FSS >4); Italic printed numerals numerics mark fatigue scores measured with fatigue scales other than FSS 
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